BioLineRx Ltd. (NASDAQ:BLRX)‘s stock had its “buy” rating reiterated by Roth Capital in a research note issued to investors on Monday. They currently have a $7.00 target price on the stock.
Other equities research analysts have also issued research reports about the stock. S&P Equity Research cut their target price on shares of BioLineRx from $1.24 to $1.10 in a research note on Friday, September 23rd. Zacks Investment Research upgraded shares of BioLineRx from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research note on Monday, August 15th. Finally, Maxim Group restated a “hold” rating and issued a $1.00 target price on shares of BioLineRx in a research note on Wednesday, September 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. BioLineRx presently has a consensus rating of “Hold” and an average price target of $2.68.
Shares of BioLineRx (NASDAQ:BLRX) traded down 2.8796% during midday trading on Monday, reaching $1.0489. The company’s stock had a trading volume of 123,172 shares. BioLineRx has a 1-year low of $0.71 and a 1-year high of $1.63. The stock has a 50 day moving average of $0.00 and a 200-day moving average of $0.00.
BioLineRx (NASDAQ:BLRX) last issued its earnings results on Tuesday, November 22nd. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by $0.01. Analysts anticipate that BioLineRx will post ($0.28) EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the company. KCG Holdings Inc. boosted its position in BioLineRx by 414.1% in the third quarter. KCG Holdings Inc. now owns 151,029 shares of the company’s stock valued at $174,000 after buying an additional 121,650 shares during the period. Morgan Stanley boosted its position in BioLineRx by 13.8% in the third quarter. Morgan Stanley now owns 551,122 shares of the company’s stock valued at $634,000 after buying an additional 66,900 shares during the period. Finally, Senvest Management LLC boosted its position in BioLineRx by 25.4% in the third quarter. Senvest Management LLC now owns 4,443,500 shares of the company’s stock valued at $5,110,000 after buying an additional 900,200 shares during the period. Hedge funds and other institutional investors own 13.53% of the company’s stock.
BioLineRx Company Profile